New Therapy Kills Deadly Bacterial Infection Affecting Cystic Fibrosis Patients
A new therapy introduced by researchers at Aston University and Birmingham Children’s Hospital has been discovered to completely kill a bacterial infection that may be deadly to cystic fibrosis sufferers and other chronic lung illness comparable to bronchiectasis.
The findings that are published in the journal Scientific Reports, present that scientists from Aston College, Mycobacterial Analysis Group, combined doses of three antibiotics—amoxicillin and imipenem-sulbactam and observed it was 100% effective in killing off the infection which is often extremely tough to treat in sufferers with cystic fibrosis.
The infection ends in a severe decline in lung function and often death.
Cystic fibrosis (CF) is a genetic illness affecting over 10,000 individuals in the UK, and there are over 70,000 folks with the condition worldwide (Cystic Fibrosis Basis), while bronchiectasis impacts 210,000 individuals in the UK.
Mycobacterium abscessus is a bacteria from the same family that causes tuberculosis, which causes severe lung infections in individuals, mainly children with lung problems, most notably cystic fibrosis.
It’s highly drug-resistant. Presently patients are given a cocktail of antibiotics that cause serious side effects along with extreme hearing loss and often don’t lead to a cure.
The scientists used samples of the pathogen taken from 16 infected cystic fibrosis patients and examined the new drug mixture to find how much was required to kill the bacteria. They discovered the amounts of amoxicillin-imipenem-sulbactam required had been low enough to be given safely to sufferers.